Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Executive Summary

• BrightMinds Biosciences Inc. closed a public offering of 1,945,000 common shares at $90.00 per share, raising gross proceeds of $175.05 million.
• The company granted underwriters a 30‑day option to purchase up to an additional 291,750 shares at the same price.
• Net proceeds are earmarked for multiple clinical programs (absence seizures, DEE, Prader‑Willi Syndrome, Phase 1 trial of BMB‑105) and general corporate working capital.

Key Details

• Offering Size: 1,945,000 common shares sold at $90.00 per share.
• Gross Proceeds: $175,050,000.
• Underwriter Option: Up to 291,750 additional shares (30‑day option) at the public offering price, less discounts/commissions.
• Use of Net Proceeds:
• Fund future clinical trials for drug candidates targeting absence seizures, Developmental and Epileptic Encephalopathies (DEE), and Prader‑Willi Syndrome.
• Initiate Phase 1 clinical trial for candidate BMB‑105.
• Support additional research & development on earlier‑phase programs.
• General corporate purposes and working capital.
• Book‑Running Managers: Jefferies, TD Cowen, Piper Sandler & Co., and Cantor acted as joint book‑running managers.
• Regulatory Filing: Shelf registration statement on Form F‑3 declared effective by the SEC on September 2 2025; offering made solely via prospectus and supplement.
• Contact Information:
• Alex Vasilkevich – Chief Operating Officer (T: 414‑731‑6422, E: [email protected])
• Lisa M. Wilson – Investor Relations (T: 212‑452‑2793, E: [email protected])

Notable Quotes

No executive quotes were included in the release.